Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Sabina Schacher"'
Autor:
Martin Fehr, Hanne Hawle, Stefanie Hayoz, Peter Thuss-Patience, Sabina Schacher, Jorge Riera Knorrenschild, Donat Dürr, Wolfram T. Knoefel, Holger Rumpold, Michael Bitzer, Martin Zweifel, Panagiotis Samaras, Ulrich Mey, Marc Küng, Ralph Winterhalder, Wolfgang Eisterer, Viviane Hess, Marie-Aline Gérard, Arnoud Templeton, Michael Stahl, Thomas Ruhstaller, for the Swiss Group for Clinical Cancer Research (SAKK), the German Esophageal Cancer Study Group, the Austrian Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT), the Fédération Francophone de Cancérologie Digestive (FFCD) / Fédération de Recherche en Chirurgie (FRENCH)
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background High rates of venous thromboembolic events (VTEs), mainly in advanced disease, are reported for patients with cancer of the upper gastrointestinal tract (stomach, pancreas) and for treatment with cisplatin. Methods Exploratory ana
Externí odkaz:
https://doaj.org/article/0081a584ac4248f78e6831be4adafd73
Autor:
Cédric M. Panje, Laura Höng, Stefanie Hayoz, Vickie E. Baracos, Evelyn Herrmann, Helena Garcia Schüler, Urs R. Meier, Guido Henke, Sabina Schacher, Hanne Hawle, Marie-Aline Gérard, Thomas Ruhstaller, Ludwig Plasswilm, for the Swiss Group for Clinical Cancer Research (SAKK)
Publikováno v:
Radiation Oncology, Vol 14, Iss 1, Pp 1-7 (2019)
Abstract Background Sarcopenia, the critical depletion of skeletal muscle mass, is an independent prognostic factor in several tumor entities for treatment-related toxicity and survival. In esophageal cancer, there have been conflicting results regar
Externí odkaz:
https://doaj.org/article/a6c19732d9914c6da5052997e4c4898e
Autor:
Sabina Schacher-Kaufmann, Miklos Pless
Publikováno v:
Case Reports in Oncology, Vol 3, Iss 2, Pp 182-188 (2010)
We describe the case of a never-smoker who received second-line erlotinib as a treatment for his non-small cell lung cancer. Within one month, acute hepatic failure developed as well as a thrombotic-thrombocytopenic microangiopathy, with fatal outcom
Externí odkaz:
https://doaj.org/article/f64990f2069b4e0797a16f8bcb34dd01
Autor:
Cédric Panje, Stefanie Hayoz, Wolfgang Eisterer, Viviane Hess, Peter Thuss-Patience, Sabina Schacher, Donat Dürr, Anna Dorothea Wagner, Michael Girschikofsky, Eric Eboulet, Michael Stahl, Thomas Ruhstaller
BACKGROUND Recurrent oesophageal cancer after the initial curative multimodality treatment is a disease condition with a poor prognosis. There is limited evidence on recurrence patterns and on the optimal therapeutic approach. METHODS We analysed the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20a7696fc1728e1e8cbf244d9127b672
Autor:
Dieter Koeberle, Ludwig Plasswilm, Roger von Moos, Piercarlo Saletti, Dirk Klingbiel, Daniela Bärtschi, Ralph Winterhalder, Martin D. Berger, Pu Yan, Arnaud Roth, György Bodoky, Panagiotis Samaras, Paola Izzo, Daniel R. Zwahlen, Daniel Rauch, Stefanie Hayoz, Urs R. Meier, Sabina Schacher, Kathrin Zaugg
Publikováno v:
European Journal of Cancer. 89:82-89
Background KRAS mutation occurs in ∼40% of locally advanced rectal cancers (LARCs). The multitarget tyrosine kinase inhibitor sorafenib has radiosensitising effects and might improve outcomes for standard preoperative chemoradiotherapy in patients
Autor:
Wilfried Budach, Ludwig Plasswilm, Hanne Hawle, Michael Stahl, Jorge Riera Knorrenschild, Wolfgang Eisterer, Peter Brauchli, Laurent Bedenne, M. Girschikofsky, Sabina Schacher, S. C. Schmidt, Viviane Hess, Stefanie Hayoz, Michael Bitzer, Christophe Mariette, Annelies Schnider, Thomas Ruhstaller, Michael Montemurro, W. Mingrone, Peter C. Thuss-Patience
Publikováno v:
Annals of Oncology
Annals of Oncology, Elsevier, 2018, 29 (6), pp.1386-1393. ⟨10.1093/annonc/mdy105⟩
Annals of Oncology, Elsevier, 2018, 29 (6), pp.1386-1393. ⟨10.1093/annonc/mdy105⟩
IF 13.926 (2017); International audience; BackgroundThis open-label, phase III trial compared chemoradiation followed by surgery with or without neoadjuvant and adjuvant cetuximab in patients with resectable esophageal carcinoma.Patients and methodsP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daf360ae9c8fb381c7ae6c8959b10142
https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01995943
https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01995943
Autor:
Miklos Pless, Sabina Schacher-Kaufmann
Publikováno v:
Case Reports in Oncology
Case Reports in Oncology, Vol 3, Iss 2, Pp 182-188 (2010)
Case Reports in Oncology, Vol 3, Iss 2, Pp 182-188 (2010)
We describe the case of a never-smoker who received second-line erlotinib as a treatment for his non-small cell lung cancer. Within one month, acute hepatic failure developed as well as a thrombotic-thrombocytopenic microangiopathy, with fatal outcom
Autor:
Richard Herrmann, R. von Moos, Piercarlo Saletti, Attila Kollár, Markus Borner, Viviane Hess, Sandro Anchisi, K. Matter, Ralph Winterhalder, Marc Kueng, Peter Brauchli, Daniel Dietrich, M. Frueh, Daniela Baertschi, Dieter Koeberle, Arnaud Roth, Peter Moosmann, Sabina Schacher, Daniel Betticher, R. A. Popescu
Publikováno v:
Koeberle, D; Betticher, D C; von Moos, R; Dietrich, D; Brauchli, P; Baertschi, D; Matter, K; Winterhalder, R; Borner, M; Anchisi, S; Moosmann, P; Kollár, Attila; Saletti, P; Roth, A; Frueh, M; Kueng, M; Popescu, R A; Schacher, S; Hess, V and Herrmann, R (2015). Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Annals of oncology, 26(4), pp. 709-714. Oxford University Press 10.1093/annonc/mdv011
Annals of Oncology, Vol. 26, No 4 (2015) pp. 709-14
Annals of Oncology, Vol. 26, No 4 (2015) pp. 709-14
In this trial, stopping bevacizumab after completion of induction chemotherapy was associated with a shorter time to progression, but no statistically significant difference in overall survival compared with the bevacizumab continuation strategy. Non
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa47d1f07a0d51e80e0b758ebebd0839
https://boris.unibe.ch/77225/1/709.full.pdf
https://boris.unibe.ch/77225/1/709.full.pdf
Autor:
Sabina Schacher, M-A. Gerard, Holger Rumpold, Peter C. Thuss-Patience, R. Winterhalden, Thomas Ruhstaller, J. Riera Knorrenschild, Viviane Hess, Michael Bitzer, Ulrich Mey, Wolfgang Eisterer, Michael Stahl, D. Dürr, Marc Kueng, Martin Zweifel, Martin Fehr, Hanne Hawle, Wolfram T. Knoefel, Stefanie Hayoz, Panagiotis Samaras
Publikováno v:
Annals of Oncology. 28:v217
Autor:
Michael Stahl, Stefanie Hayoz, Viviane Hess, S. C. Schmidt, Anna Dorothea Wagner, Thomas Ruhstaller, Michael Bitzer, Ludwig Plasswilm, Sabina Schacher-Kaufmann, Christophe Mariette, Annelies Schnider, Wolfgang Eisterer, Michael Girschikofsky, Walter Mingrone, Wilfried Budach, Hanne Hawle, Jorge Riera-Knorrenschild, Peter Brauchli, Laurent Bedenne, Peter C. Thuss-Patience
Publikováno v:
Journal of Clinical Oncology. 35:4019-4019
4019 Background: We compared chemoradiotherapy followed by surgery with the addition of neoadjuvant and adjuvant cetuximab (cetux) in patients with esophageal carcinoma. Methods: Pts with resectable esophageal cancer (T2N1-3;T3-4aNx) received two cyc